Literature DB >> 25386935

T cell-mediated hypersensitivity reactions to drugs.

Rebecca Pavlos1, Simon Mallal, David Ostrov, Soren Buus, Imir Metushi, Bjoern Peters, Elizabeth Phillips.   

Abstract

The immunological mechanisms driving delayed hypersensitivity reactions (HSRs) to drugs mediated by drug-reactive T lymphocytes are exemplified by several key examples and their human leukocyte antigen (HLA) associations: abacavir and HLA-B*57:01, carbamazepine and HLA-B*15:02, allo-purinol and HLA-B*58:01, and both amoxicillin-clavulanate and nevirapine with multiple class I and II alleles. For HLA-restricted drug HSRs, specific class I and/or II HLA alleles are necessary but not sufficient for tissue specificity and the clinical syndrome. Several models have been proposed to explain the immunopathogenesis of severe T cell-mediated drug HSRs, and our increased understanding of the risk factors and mechanisms involved in the development of these reactions will further the development of sensitive and specific strategies for preclinical screening that will lead to safer and more cost-effective drug design.

Entities:  

Keywords:  Stevens-Johnson syndrome; altered peptide; human leukocyte antigen; major histocompatibility complex; pharmacogenomics; toxic epidermal necrolysis

Mesh:

Substances:

Year:  2014        PMID: 25386935      PMCID: PMC4295772          DOI: 10.1146/annurev-med-050913-022745

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  77 in total

Review 1.  The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.

Authors:  M Pirmohamed; G P Aithal; E Behr; A Daly; D Roden
Journal:  Clin Pharmacol Ther       Date:  2011-06       Impact factor: 6.875

Review 2.  HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis.

Authors:  Sandeep Grover; Ritushree Kukreti
Journal:  Pharmacogenet Genomics       Date:  2014-02       Impact factor: 2.089

3.  Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.

Authors:  Thorsten Lehr; Jing Yuan; David Hall; Heike Zimdahl-Gelling; Hans Guenter Schaefer; Alexander Staab; Thomas R MacGregor; Supriya Jayadev
Journal:  Pharmacogenet Genomics       Date:  2011-11       Impact factor: 2.089

4.  HLA association of amoxicillin-clavulanate--induced hepatitis.

Authors:  M L Hautekeete; Y Horsmans; C Van Waeyenberge; C Demanet; J Henrion; L Verbist; R Brenard; C Sempoux; P P Michielsen; P S Yap; J Rahier; A P Geubel
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

5.  Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Zhi-Sheng Liu; Chien-Hsiun Chen; Mo-Song Hsih; Rosaline Chung-yee Hui; Chia-Yu Chu; Yuan-Tsong Chen
Journal:  Pharmacogenomics       Date:  2010-03       Impact factor: 2.533

6.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

7.  Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.

Authors:  C F Spraggs; L R Parham; C M Hunt; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  2012-02-22       Impact factor: 6.875

8.  Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

Authors:  Diana Chessman; Lyudmila Kostenko; Tessa Lethborg; Anthony W Purcell; Nicholas A Williamson; Zhenjun Chen; Lars Kjer-Nielsen; Nicole A Mifsud; Brian D Tait; Rhonda Holdsworth; Coral Ann Almeida; David Nolan; Whitney A Macdonald; Julia K Archbold; Anthony D Kellerher; Debbie Marriott; Simon Mallal; Mandvi Bharadwaj; Jamie Rossjohn; James McCluskey
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

9.  Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.

Authors:  Daniel F Carr; Mas Chaponda; Andrea L Jorgensen; Elena Cornejo Castro; Joep J van Oosterhout; Saye H Khoo; David G Lalloo; Robert S Heyderman; Ana Alfirevic; Munir Pirmohamed
Journal:  Clin Infect Dis       Date:  2013-01-29       Impact factor: 9.079

10.  Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.

Authors:  Laura Dickinson; Masautso Chaponda; Daniel F Carr; Joep J van Oosterhout; Johnstone Kumwenda; David G Lalloo; Munir Pirmohamed; Robert S Heyderman; Saye H Khoo
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

View more
  47 in total

Review 1.  The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015.

Authors:  Roni P Dodiuk-Gad; Cristina Olteanu; Wen-Hung Chung; Neil H Shear
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

2.  Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.

Authors:  Lisa M Wheatley; Marshall Plaut; Julie M Schwaninger; Aleena Banerji; Mariana Castells; Fred D Finkelman; Gerald J Gleich; Emma Guttman-Yassky; Simon A K Mallal; Dean J Naisbitt; David A Ostrov; Elizabeth J Phillips; Werner J Pichler; Thomas A E Platts-Mills; Jean-Claude Roujeau; Lawrence B Schwartz; Lauren A Trepanier
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

3.  Characterization of 108 Genomic DNA Reference Materials for 11 Human Leukocyte Antigen Loci: A GeT-RM Collaborative Project.

Authors:  Maria P Bettinotti; Deborah Ferriola; Jamie L Duke; Timothy L Mosbruger; Nikolaos Tairis; Lawrence Jennings; Lisa V Kalman; Dimitri Monos
Journal:  J Mol Diagn       Date:  2018-06-26       Impact factor: 5.568

Review 4.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

5.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

6.  A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms.

Authors:  Francois X Rwandamuriye; Abha Chopra; Katherine C Konvinse; Linda Choo; Jason A Trubiano; Christian M Shaffer; Mark Watson; Simon A Mallal; Elizabeth J Phillips
Journal:  J Mol Diagn       Date:  2019-05-31       Impact factor: 5.568

Review 7.  Drug Hypersensitivity.

Authors:  Ruwen Böhm; Ehrhardt Proksch; Thomas Schwarz; Ingolf Cascorbi
Journal:  Dtsch Arztebl Int       Date:  2018-07-23       Impact factor: 5.594

Review 8.  Recent Advances in Application of Pharmacogenomics for Biotherapeutics.

Authors:  Pramod B Mahajan
Journal:  AAPS J       Date:  2016-03-23       Impact factor: 4.009

9.  Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis.

Authors:  Jason A Trubiano; Alec Redwood; Kaija Strautins; Rebecca Pavlos; Emily Woolnough; Christina C Chang; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2016-11-23

Review 10.  New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity.

Authors:  Aaron W Michels; David A Ostrov
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.